

Table of Contents Complaint Exhibits

Exhibit	Document
A	Mifepristone U.S. Post-Marketing Adverse Events Summary through 06/30/2022
B	Center for Drug Evaluation & Research, Application No. 020687Orig1s020, Mifeprex Medical Review(s)
C	Approved Risk Evaluation and Mitigation Strategies (REMS) 2023
D	FDA NDA 20-687 Approval Memo, Sept. 28, 2000
E	Food and Drug Administration Approval and Oversight of the Drug Mifeprex
F	2016 FDA Letter to Am. Ass'n of Pro-Life Obstetricians & Gynecologists, Christian Medical & Dental Associations, and Concerned Women for America denying 2002 Citizen Petition, Docket No. FDA-2002-P0364, Mar. 29, 2016
G	FDA Final Risk Evaluation and Mitigation Strategy (REMS) Review, Oct. 10, 2013
H	Letter from Society of Family Planning (SFP), <i>et al.</i> , to Stephen Ostroff, M.D., Robert M. Califf, M.D., & Janet Woodcock, M.D., Feb. 4, 2016
I	Center for Drug Evaluation & Research, Application No: 020687Orig1s020, Cross Discipline Team Leader Review
J	U.S. Food & Drug Admin., Center for Drug Evaluation & Research, Application No. 020687Orig1s020, Mifeprex Summary Review, Mar. 29, 2016
K	U.S. Food & Drug Admin., Center for Drug Evaluation & Research, Application No. 020687Orig1s020, Mifeprex Risk Assessment and Risk Mitigation Review(s): Letter from Janet Woodcock, M.D., Regarding NDA 020687, Mar. 28, 2016
L	2023 Risk Evaluation and Mitigation Strategy (REMS) Single Shared System for Mifepristone 200 mg
M	U.S. Food & Drug Admin., Full Prescribing Information for Mifeprex (Mifeprex Labeling)
N	U.S. Food & Drug Admin., Center for Drug Evaluation & Research, Application No. 020687Orig1s020, Mifeprex Risk Assessment and Risk Mitigation Review(s): REMS Modification Memorandum (Mar. 29, 2016)

Exhibit	Document
O	Mifepristone Prescriber Agreement Forms
P	Mifepristone Pharmacy Agreement Forms
Q	Mifepristone Patient Agreement Form
R	Mifepristone Medication Guide
S	U.S. Food & Drug Admin., Center for Drug Evaluation & Research, Letter from Patrizia Cavazzoni, M.D., Regarding Docket No. FDA-2022-P-2425, Jan. 3, 2023